

Revision date: 15-Dec-2006

Version: 2.1

Page 1 of 6

# 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

# Material Name: Chloramphenicol Ophthalmic Ointment 1%

Trade Name:	Chloromycetin®
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as antibiotic agent

# 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS List	%
Chloramphenicol	56-75-7	200-287-4	1

Ingredient	CAS Number	EU EINECS List	%
Plastibase 30 W Sterile	Mixture	Not listed	*
Liquid paraffin	92062-35-6	295-550-3	*

**Additional Information:** 

#### \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

# 3. HAZARDS IDENTIFICATION

Appearance:	ointment
Signal Word:	DANGER
Statement of Hazard:	May cause cancer.
	May cause genetic defects.
	Suspected of damaging fertility or the unborn child.
	May cause adverse effects on blood forming organs
Additional Hazard Information:	
Short Term:	Acute toxicity following ingestion is not expected.
Long Term:	Repeated or prolonged exposure may cause effects similar to those seen in clinical use.
U	Repeat-dose studies in animals have shown a potential to cause adverse effects on the
	hematological and reproductive systems.

Material Name: Chloramphenicol Ophthalmic Ointment 1% Revision date: 15-Dec-2006

Known Clinical Effects: EU Indication of danger:	The most serious adverse reaction seen with the use of chloramphenicol is reversible, dose related, bone marrow depression. Serious and fatal blood effects (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have also occurred after chlormaphenicol treatment. The aplastic anemia seen from treatment may terminate in leukemia. GI and CNS effects have occurred infrequently and hypersensitivity reactions have been reported rarely. Ophthalmic use of chloramphenicol has resulted in optic neuritis, impaired central vision, and injury to the optic and peripheral nerves. Prolonged treatment may result in optic neuropathy. Sensitization, manifested as periocular and periauricular dermatitis, has also been reported. T - Toxic
EU Hazard Symbols:	
EU Risk Phrases:	R45 - May cause cancer.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES	
Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.
Ingestion:	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.
Inhalation:	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.
5. FIRE FIGHTING MEASUR	ES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.
Fire / Explosion Hazards:	Not determined

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.					
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. area thoroughly.	Collect spill with absorbent material. Clean spill				

Material Name: Chloramphenicol Ophthalmic Ointment 1% Revision date: 15-Dec-2006

Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.				
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.				
7. HANDLING AND STORAGE					
General Handling:	Avoid contact with eyes. Avoid contact with skin and clothing. Wash thoroughly after handling.				
Storage Conditions:	Keep in tightly closed containers away from heat and light. Store in a cool, dry, well-ventilated area.				
8. EXPOSURE CONTROLS / PE	ERSONAL PROTECTION				
Chloramphenicol Pfizer OEL TWA-8 Hr:	0.5 mg/m³				
Analytical Method:	Analytical method available for chloramphenicol. Contact Pfizer Inc for further information.				
Engineering Controls:	Engineering controls should be used as the primary means to control exposures.				
Personal Protective Equipment:					

Hands:	Wear impervious gloves if skin contact is possible.
Eyes:	Safety glasses or goggles
Skin:	Wear protective clothing when working with large quantities.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate
	respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:OintmentColor:ColorlessMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY				
Stability:	Stable under normal conditions of use.			
Conditions to Avoid:	Keep away from excessive heat and flames.			
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers.			
Hazardous Decomposition Products	When heated to decomposition this compound emits very toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides and hydrogen chloride gas.			
Polymerization:	Will not occur.			

# 11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient

#### Acute Toxicity: (Species, Route, End Point, Dose)

Chloramphenicol

# Material Name: Chloramphenicol Ophthalmic Ointment 1% Revision date: 15-Dec-2006

Page 4 of 6 Version: 2.1

Mouse Oral LD50 2300 mg/kg Mouse Oral LD50 1500 mg/kg Rat Oral LD50 2500 mg/kg Rat (M/F) Intravenous LD 50 170/171 mg/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

Chloramphenicol Eye Irritation Rabbit Non-irritating

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Chloramphenicol

14 Day(s) Dog Oral 75 mg/kg/day NOAEL Blood 60 Day(s) Rat Oral 60 mg/kg LOAEL None identified 14 Day(s) Mouse Oral 33600 mg/kg LOAEL Liver

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Chloramphenicol

Reproductive & Fertility-Males	Rat	100 r	ng/kg/da	y NOAE	EL Fertilit	ty
Embryo / Fetal Development	Rat	Oral	500 mg	g/kg/day	LOAEL	Fetotoxicity
Embryo / Fetal Development	Mouse	Oral	500	mg/kg/day	/ LOAEL	Fetotoxicity
Embryo / Fetal Development	Rabbit	Oral	500	mg/kg/day	LOAEL	Fetotoxicity
Embryo / Fetal Development	Rat	Oral 23	g/kg	LOEL 1	<b>Feratogenic</b>	

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Chloramphenicol

Bacterial Mutagenicity (Ames)BacteriaNegativeDirect DNA DamageRat HepatocytePositiveIn Vitro MicronucleusMouse LymphomaPositiveChromosome AberrationHuman LymphocytesPositive

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Chloramphenicol

104 Week(s)	Mouse	Oral	500 mg/L/day	NOAEL	Lymphatic system
104 Week(s)	Mouse	Oral	500 mg/L/day	LOAEL	Lymphatic system, Liver

Carcinogen Status:

See below

Chloramphenicol IARC: NTP:

OSHA:

Group 2A Listed Present

# **12. ECOLOGICAL INFORMATION**

**Environmental Overview:** 

The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Material Name: Chloramphenicol Ophthalmic Ointment 1% Revision date: 15-Dec-2006

# 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

# 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

EU Indication of danger:	T - Toxic
EU Risk Phrases:	R45 - May cause cancer.
EU Safety Phrases:	S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use.

OSHA Label: DANGER May cause cancer. May cause genetic defects. Suspected of damaging fertility or the unborn child. May cause adverse effects on blood forming organs

#### Canada - WHMIS: Classifications

#### WHMIS hazard class: Class D, Division 2, Subdivision A



Liquid paraffin Australia (AICS): EU EINECS List

Chloramphenicol California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS):

carcinogen, initial date 10/1/89 Listed Present

Standard for the Uniform Scheduling for Drugs and Poisons: EU EINECS List Schedule 4 200-287-4

Present

295-550-3

Material Name: Chloramphenicol Ophthalmic Ointment 1% Revision date: 15-Dec-2006

# **16. OTHER INFORMATION**

Reasons for Revision:	Updated Section 3 - Hazard Identification. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet